193. Prader-Willi syndrome
95 clinical trials,   104 drugs   (DrugBank: 27 drugs),   50 drug target genes,   63 drug target pathways

Searched query = "Prader-Willi syndrome"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

Search in Page e.g. "Phase 3", "Not recruiting", "Japan"
5 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1EUCTR2014-004415-37-NL
(EUCTR)
07/03/201617/08/2015Effect of liraglutide for weight management in children with Prader-Willi SyndromeEffect of liraglutide for weight management in paediatric subjects with Prader-Willi Syndrome. A randomised, placebo controlled, parallel group, multi-centre, multinational trial with a 16-week double-blind period and 36-week open-label period Obesity(Prader-Willi syndrome)
MedDRA version: 18.1;Level: PT;Classification code 10029883;Term: Obesity;System Organ Class: 10027433 - Metabolism and nutrition disorders;Therapeutic area: Diseases [C] - Nutritional and Metabolic Diseases [C18]
Trade Name: Saxenda
INN or Proposed INN: LIRAGLUTIDE
Novo Nordisk A/SNULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
60United States;European Union;Canada;Turkey;Australia;Netherlands;New Zealand
2EUCTR2014-004415-37-IT
(EUCTR)
10/11/201529/07/2015Effect of liraglutide for weight management in children with Prader-Willi SyndromeEffect of liraglutide for weight management in paediatric subjects with Prader-Willi Syndrome. A randomised, placebo controlled, parallel group, multi-centre, multinational trial with a 16-week double-blind period and 36-week open-label period Obesity(Prader-Willi syndrome)
MedDRA version: 18.0;Level: PT;Classification code 10029883;Term: Obesity;System Organ Class: 10027433 - Metabolism and nutrition disorders;Therapeutic area: Diseases [C] - Nutritional and Metabolic Diseases [C18]
Trade Name: Saxenda
INN or Proposed INN: LIRAGLUTIDE
Novo Nordisk A/SNULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
60Phase 3Turkey;Australia;Netherlands;New Zealand;Italy;France;United States;European Union;Canada
3NCT02527200
(ClinicalTrials.gov)
November 9, 201517/8/2015Effect of Liraglutide for Weight Management in Paediatric Subjects With Prader-Willi SyndromeEffect of Liraglutide for Weight Management in Paediatric Subjects With Prader-Willi Syndrome.Metabolism and Nutrition Disorder;ObesityDrug: liraglutide;Drug: placeboNovo Nordisk A/SNULLCompleted6 Years18 YearsAll56Phase 3United States;Australia;Canada;France;Italy;Netherlands;New Zealand;Turkey
4NCT01542242
(ClinicalTrials.gov)
February 201221/2/2012Liraglutide Use in Prader-Willi SyndromeDiabetes Mellitus Type 2;Prader Willi SyndromeDrug: LiraglutideVancouver General HospitalNovo Nordisk A/STerminated19 YearsN/AMale1Phase 4Canada
5EUCTR2014-004415-37-FR
(EUCTR)
04/08/2015Effect of liraglutide for weight management in children with Prader-Willi SyndromeEffect of liraglutide for weight management in paediatric subjects with Prader-Willi Syndrome. A randomised, placebo controlled, parallel group, multi-centre, multinational trial with a 16-week double-blind period and 36-week open-label period Obesity(Prader-Willi syndrome)
MedDRA version: 18.0;Level: PT;Classification code 10029883;Term: Obesity;System Organ Class: 10027433 - Metabolism and nutrition disorders;Therapeutic area: Diseases [C] - Nutritional and Metabolic Diseases [C18]
Trade Name: Saxenda
INN or Proposed INN: LIRAGLUTIDE
Novo Nordisk A/SNULLNAFemale: yes
Male: yes
60Phase 3United States;France;European Union;Canada;Turkey;Australia;Netherlands;Italy;New Zealand